SCHEDULE 13G/A: BlackRock Boosts Bio-Rad Class A Stock Stake to 7.4%

BlackRock, Inc. has reported an aggregate beneficial ownership of 7.4% of Bio-Rad Laboratories, Inc.'s Class A Stock, totaling 1,618,123 shares.

Summary

• BlackRock, Inc. filed an Amendment No. 12 to Schedule 13G regarding its beneficial ownership in Bio-Rad Laboratories, Inc. Class A Stock.
• As of September 30, 2025, BlackRock, Inc. beneficially owns 1,618,123 shares of Bio-Rad Laboratories, Inc. Class A Stock.
• This ownership represents 7.4% of the total outstanding Class A Stock.
• BlackRock, Inc. holds sole voting power over 1,561,852 shares and sole dispositive power over 1,618,123 shares.
• No shared voting or dispositive power is reported.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. A major institutional investor like BlackRock holding a significant stake (7.4%) in Bio-Rad Laboratories, Inc. suggests a degree of confidence in the company. The filing is a routine disclosure and does not contain negative information, but also no new positive operational or financial news from the issuer itself.

Positives

• A significant institutional investor like BlackRock maintaining or increasing its stake can signal confidence in the company's long-term prospects.
• The investment is stated to be in the ordinary course of business, indicating a standard portfolio allocation rather than an activist position.

Future Outlook

The filing does not provide forward-looking statements or guidance from Bio-Rad Laboratories, Inc. It solely reports BlackRock, Inc.'s current beneficial ownership position.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

BlackRock, as one of the world's largest asset managers, frequently discloses significant stakes in publicly traded companies as part of its investment management activities. This filing reflects a routine disclosure of its passive investment in a healthcare and life sciences company, Bio-Rad Laboratories, Inc., which operates in a sector often favored by institutional investors for its growth potential and defensive characteristics.

Stakeholder Impact

• Shareholders may view BlackRock's continued significant ownership as a positive signal, potentially reinforcing market confidence in Bio-Rad Laboratories, Inc.

Key Dates

Recommendation

A 'hold' recommendation is appropriate as this filing primarily discloses a significant institutional ownership stake by BlackRock, Inc. While a large institutional investment can be a positive indicator of confidence, the Schedule 13G itself does not provide new operational, financial, or strategic information about Bio-Rad Laboratories, Inc. that would warrant a 'buy' or 'sell' action. It confirms a substantial, passive investment, suggesting stability rather than a catalyst for immediate price movement based solely on this disclosure.

Keywords

BlackRock, Bio-Rad Laboratories, Class A Stock, Beneficial Ownership, Institutional Investor, SEC Filing, Schedule 13G, Healthcare, Biotechnology